A myeloma stage can look like a final verdict on a report, but it can’t describe everything about your health. If you’re facing a new diagnosis in Malaysia, the stage is one part of a wider assessment. Your doctor also needs to know whether the disease is active, whether it has affected your organs, and what the myeloma cells show in laboratory tests.
Understanding how those findings fit together can make your next haematology appointment easier to follow.
Quick Answer: How Is Multiple Myeloma Staged?
Doctors first confirm the diagnosis using blood and urine tests, bone marrow findings, and imaging where needed. They then use a myeloma-specific staging system to describe risk. The International Staging System (ISS) uses two blood markers. The Revised ISS (R-ISS) also considers lactate dehydrogenase (LDH) and chromosome findings from myeloma cells. A newer system, R2-ISS, divides patients into four risk groups.
Staging estimates risk across groups of patients. Your specialist must interpret your stage alongside symptoms, kidney function, scans, general health, and treatment response.
5 Key Takeaways
- A stage describes myeloma risk; it doesn’t tell you which treatment you must receive.
- ISS uses serum beta-2 microglobulin and albumin, while R-ISS adds LDH and selected chromosome findings.
- Blood tests alone can’t establish whether you have active multiple myeloma.
- Bone marrow testing and imaging help doctors assess the cells and any damage they may be causing.
- Ask your haematologist which results are confirmed, which remain pending, and what your stage means for your care.
Diagnosis Comes Before Staging
Multiple myeloma develops in plasma cells, the cells in bone marrow that normally make antibodies. Abnormal plasma cells may produce an unusual protein and interfere with healthy blood-cell production. They can also affect bones and kidneys.
A suspected diagnosis and an assigned stage answer different questions. Your specialist first establishes what condition you have and whether it needs treatment. Only then can a staging score be put in context.
Active myeloma and smoldering myeloma differ
Smoldering multiple myeloma means abnormal plasma cells or proteins are present, but the findings don’t meet the criteria for active disease. It generally calls for monitoring rather than immediate treatment. Active myeloma meets defined diagnostic criteria, which may include organ damage or certain biological findings.
Doctors use the term CRAB when checking for myeloma-related organ effects, such as kidney or bone problems. They also assess calcium levels and blood counts. The International Myeloma Working Group (IMWG) recognises additional biological findings that can establish active disease before obvious organ damage develops. Its diagnostic criteria for multiple myeloma explain why a raised abnormal protein result isn’t enough on its own.
A stage isn’t a map of where cancer has spread
You may know stages from breast or lung cancer, where the number often describes a tumour’s size and spread. Myeloma staging works differently. Its scores combine blood markers and, in newer systems, features of the myeloma cells.
For that reason, a higher-numbered stage doesn’t automatically tell you how much bone disease a scan will show. Likewise, someone with a lower stage may still need prompt attention for a particular symptom or complication.
The Tests Behind Your Myeloma Assessment
Your haematologist brings several results together rather than relying on one number. Some tests help confirm disease, while others show organ effects or contribute to risk assessment.
Blood and urine tests show proteins and organ effects
A full blood count checks for anaemia. Calcium and tests for kidney problems look for issues that may need attention. Doctors may also measure abnormal proteins and serum free light chains, parts of antibodies that myeloma cells can produce. Urine tests can add information about abnormal protein and kidney effects.
Staging blood markers include albumin and LDH. However, your specialist won’t interpret an isolated abnormal result as proof of a particular stage. Reduced kidney filtration can complicate the interpretation of some markers. Kidney problems also matter to care decisions in their own right.
Marrow samples and scans answer different questions
A bone marrow aspiration and biopsy allow a laboratory to examine plasma cells. Testing the sample can include fluorescence in situ hybridisation (FISH), which looks for selected chromosome changes in the myeloma cells. These findings help your specialist assess risk; they don’t replace the rest of the diagnosis.
Imaging checks for bone and marrow findings that blood tests cannot show. Depending on your symptoms and the tests available, your team may consider whole-body low-dose CT, PET-CT, or MRI. Ask what a recommended scan is intended to clarify. A marrow sample and a scan provide different information, so neither tells the whole story by itself.
How the ISS Assigns a Multiple Myeloma Stage
The original international staging system (ISS) uses two blood-test results: beta-2 microglobulin and serum albumin. It places newly diagnosed myeloma into stages I, II, or III. The International Myeloma Foundation’s ISS overview describes the system and its later revision.
What the two blood markers tell your doctor
The marker can rise when myeloma burden is greater, but kidney function also affects its level. Albumin is a protein made by the liver, and its blood level adds prognostic information. Neither measurement directly counts myeloma cells in every part of your body.
Under the ISS, stage I requires a marker level below 3.5 mg/L and an albumin level of at least 3.5 g/dL. Stage III involves a marker level of 5.5 mg/L or higher. Stage II covers results that meet neither stage I nor stage III.
Why the ISS number has limits
The ISS is useful because the two tests are widely available. Yet patients in the same ISS stage can have myeloma cells with different biological features. The score also doesn’t describe bone pain, infection, fitness, or how well treatment works later.
If your report gives an ISS stage but no chromosome results yet, ask whether the risk assessment is complete. A preliminary discussion may change when outstanding tests return.
What the R-ISS Adds to Staging
The Revised International Staging System builds on ISS. It considers LDH, a blood marker, and selected higher-risk chromosome findings identified through FISH. Like ISS, it assigns stages I, II, and III. The American Cancer Society’s myeloma staging guide explains its patient-facing use.
LDH and FISH add information about risk
LDH may give your doctor another indication of disease behaviour. FISH examines the myeloma cells for chromosome changes associated with different levels of risk. Your report may describe these findings separately, so ask your specialist which results were used for your R-ISS stage.
A FISH result concerns changes found in the sampled myeloma cells. Don’t assume it means you inherited a condition or that relatives need testing. Your doctor can explain whether any separate family-risk question applies.
Stage III needs a complete set of results
A high beta-2 microglobulin level alone shouldn’t be read as an R-ISS stage III diagnosis. The revised system combines findings, so your team needs the relevant blood and FISH results before explaining the final category.
If a report says “high risk,” ask which test supports that description and whether it refers to ISS, R-ISS, or another assessment. A risk category describes a group, not a guaranteed outcome for you. It also cannot predict your response to a particular treatment.
Where R2-ISS Fits
The second revision, called R2-ISS, is another way to group newly diagnosed patients by risk. Rather than assigning everyone to one of three R-ISS groups, its scoring approach identifies four groups. The published R2-ISS study describes its purpose of separating patients within the broad intermediate-risk range more clearly.
You may still see ISS or R-ISS on your hospital letter. That doesn’t mean your assessment is automatically out of date. Ask which system your haematologist is using, whether all required results are available, and how the category affects discussions in your case.
A newer score adds detail to a risk conversation. It doesn’t remove the need to assess your current symptoms, organ function, scan findings, or fitness.
Why Your Stage Isn’t Your Treatment Plan
Once active myeloma is confirmed, your haematologist considers more than the starting stage. Kidney function, bone problems, other medical conditions, general fitness, and the disease’s biological features can all affect treatment suitability.
Treatment decisions use the whole clinical picture
Cancer treatment options for myeloma may involve combinations of medicines, supportive care, and, for suitable patients, a discussion about stem cell transplantation. Your specialist decides what to recommend after reviewing your circumstances. A person with smoldering disease may instead need regular monitoring.
Treatment response matters too. Doctors follow results over time to see whether myeloma is responding or becoming more active. Your stage at diagnosis remains part of your record, but current findings guide later decisions.
Another specialist can review an unclear plan
If results seem inconsistent or you face a major treatment decision, you can ask whether a medical second opinion would help. Another qualified specialist may confirm your existing plan, clarify a finding, or suggest further assessment. A different opinion doesn’t mean your first doctor was wrong, and it won’t necessarily change treatment.
Bring complete laboratory, bone marrow, FISH, and scan reports to any review. Missing results can make a cancer treatment plan review less useful.
Questions to Ask Your Haematologist in Malaysia
Test availability, appointment timing, and costs can differ between Malaysian hospitals. Some specialised samples may need to go to another laboratory. Before making decisions, ask your team:
- Do my results meet the criteria for active myeloma, or am I being monitored for smoldering disease?
- What are my ISS and R-ISS stages, and are any blood or FISH results still pending?
- What did my bone marrow examination and scans show beyond the staging score?
- Does my kidney function need attention now, and does it affect how you read my results?
- Which treatment or monitoring approach fits my health, and what would make the plan change?
- Which tests are done on-site, how long might other results take, and what does the cost estimate include?
You can ask for a plain-language explanation of any term you don’t understand. Keeping copies of your reports also makes follow-up appointments or another specialist review easier to organise.
Frequently Asked Questions
Can a blood test alone stage multiple myeloma?
ISS uses blood-test results, but a full assessment goes further. Your doctor must establish the diagnosis first. R-ISS also needs information beyond routine blood markers, including selected chromosome findings from the myeloma cells.
Does stage III mean myeloma is untreatable?
No stage number, by itself, tells you what treatment will achieve. Stage III indicates a higher-risk category within the relevant system. Your specialist still needs to discuss suitable options and interpret the number alongside your overall health and other findings.
Why do I need imaging if my blood tests already show myeloma?
Blood tests cannot show every bone or marrow change. Imaging can help identify findings that affect diagnosis, symptom care, or treatment discussions. Your specialist will choose a scan based on the question that needs answering.
Understanding Your Stage in Context
A stage can make a complicated diagnosis easier to describe, but it cannot replace your full medical picture. The most useful question is what your blood, marrow, and scan results mean together for your next decision.
Ask your haematologist to explain the stage shown on your report, any results still pending, and how both affect your individual plan.
Medical disclaimer: This content is for general educational purposes only. It may not apply to every patient and is not medical advice, a diagnosis, or a treatment recommendation. Consult your own doctor, oncologist, or qualified healthcare professional before making medical decisions.
